Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tscan Therapeutics, Inc.

1.80
+0.12007.14%
Post-market: 1.810.0100+0.56%19:44 EDT
Volume:213.36K
Turnover:380.84K
Market Cap:101.86M
PE:-0.77
High:1.83
Open:1.68
Low:1.66
Close:1.68
Loading ...

TScan Therapeutics to Present at Jefferies Global Healthcare Conference

Reuters
·
28 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)

TIPRANKS
·
25 May

Lynx1 Capital Management LP Reports Acquisition of Common Shares of TScan Therapeutics Inc

Reuters
·
22 May

Morgan Stanley Keeps Their Buy Rating on TScan Therapeutics (TCRX)

TIPRANKS
·
19 May

TScan Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
07 May

Barclays Sticks to Its Buy Rating for TScan Therapeutics (TCRX)

TIPRANKS
·
07 May

TScan Therapeutics Q1 Net Income USD -34.127 Million

Reuters
·
06 May

TScan Therapeutics Q1 EPS $(0.26) Beats $(0.29) Estimate, Sales $2.17M Beat $1.10M Estimate

Benzinga
·
06 May

TScan Therapeutics Q1 Operating Expenses USD 38.421 Million

THOMSON REUTERS
·
06 May

TScan Therapeutics Q1 Collaboration and License Revenue USD 2.171 Million

THOMSON REUTERS
·
06 May

TScan Therapeutics: on-Track to File Ind Application for Tsc-102-a0301 to FDA in H2

THOMSON REUTERS
·
06 May

TScan Therapeutics Q1 Basic EPS USD -0.26

THOMSON REUTERS
·
06 May

TScan Therapeutics Inc. to Present at American Society of Gene and Cell Therapy Annual Meeting

Reuters
·
29 Apr

Press Release: TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Dow Jones
·
29 Apr

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
31 Mar

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

GlobeNewswire
·
27 Mar

TScan Therapeutics Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
15 Mar

TScan Therapeutics Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $10

THOMSON REUTERS
·
14 Mar

TScan Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
07 Mar

Barclays Remains a Buy on TScan Therapeutics (TCRX)

TIPRANKS
·
07 Mar